Alkeus Pharmaceuticals

Recent Finacing

Series B

Recent Raise

$150M

Alkeus Pharmaceuticals (Cambridge, MA) develops precision, disease‑modifying therapies for retinal disorders; lead candidate gildeuretinol (ALK‑001) is in clinical trials for Stargardt disease and geographic atrophy.

Founded 2011

Massachusetts, United States

1-10

Private

alkeuspharma.com

Highlights

Focus Areas

Biotechnology

Medical

Medical Device

Pharmaceutical

Recent Investors

Financials

$150M

Total Raised

1

Funding round

4

Investors

Team

Upgrade to view the team

See the team members at Alkeus Pharmaceuticals.